CN

Yong Wang

This inventor holds 0 USPTO granted patents, plus 23 CIPO patents.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yong Wang. Retrieved from https://idiyas.com/inventor/yong-wang-vjempikg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

 

Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: The Journey of Inventor Yong Wang in the Pharmaceutical Industry

Introduction: Yong Wang, a dedicated professional in the pharmaceutical sector, has made noteworthy contributions to the field through his work at prominent companies in China. Despite holding no patents, his experience in innovative environments highlights his potential influence in the industry.

Latest Patents: As of now, Yong Wang does not hold any patents registered in the innovation database. However, his expertise and collaborative efforts suggest that he may play a crucial role in future developments.

Career Highlights: Wang has worked for Nanjing Sanhome Pharmaceutical Co., Ltd. and Nextex Innovations Incorporation Limited. His tenure at these organizations reflects his commitment to advancing health-related solutions and contributing to pharmaceutical innovation.

Collaborations: Throughout his career, Yong Wang has collaborated with various industry professionals, including Qifeng Song. These partnerships are vital for nurturing innovative ideas and paving the way for potential future breakthroughs.

Conclusion: Although Yong Wang currently does not hold any patents, his background and collaborations in the pharmaceutical industry position him as a promising innovator. His experiences at established companies could lead to significant future contributions in the realm of inventions and innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…